Suscribete

The 2024 Impact Report of the Cancer Research Institute

Executive Summary   Since our founding in 1953, the Cancer Research Institute (CRI) has been at the forefront...

Cancer Research Institute Awards Over $22 Million in Grants to Fuel Immunotherapy Innovations

NEW YORK – August 8, 2024 — As the leading nonprofit organization committed to revolutionizing cancer treatment...

Cancer Research Institute Announces New Lloyd J. Old STARs Class

New York, NY – August 5, 2024 – The Cancer Research Institute (CRI) proudly announces the newest...

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer

REDWOOD CITY, Calif., May 8, 2024 — Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the...

New Survey of U.S. Oncologists Reveals Where More Work Can Be Done to Research Treatments for Advanced Non-Small Cell Lung Cancer

Survey examined oncologists’ perspective on treatment options and priorities, comorbidities and other clinical characteristics of patients with...

CRI CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey on Immunotherapy and Her Tenure

NEW YORK – Jill O’Donnell-Tormey, PhD, CEO and director of scientific affairs at the Cancer Research Institute...

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.